CN
News & Events
Award Ceremony of 2018 “Dushu Lake Prize” Selection Activities of China Pharmaceutical Innovation Brand Was Successfully Held in Suzhou
News & Events 2019.01.09 455

On the evening of September 17, 2018, the award ceremony of 2018 “Dushu Lake Prize” Selection Activities of China Pharmaceutical Innovation Brand (hereinafter referred to as the Selection Activities) was successfully held in Suzhou Culture & Art Centre. The Selection Activities was co-hosted by China Pharmaceutical Innovation and Research Development Association (PhIRDA), Suzhou Industrial Park and People.cn, and was broadcast by People.cn and Suzhou TV Station. Heavyweight guests gathered at the award ceremony and presented awards for the best projects, including He Wei, Vice Chairperson of CPPCC National Committee, Executive Vice Chairman of the Central Committee of the Chinese Peasants and Workers Democratic Party, Zhou Jianmin, Vice Chairperson of Jiangsu Provincial Committee of CPPCC, Li Yaping, Deputy Secretary of Suzhou Municipal Party Committee, Mayor of Suzhou, Wu Qingwen, Member of the Standing Committee of CPC Suzhou Committee, Secretary of SIP Working Committee, Zhou Jun, Vice Chairperson of Suzhou Committee of CPPCC, Chairman of Suzhou Municipal Committee of Chinese Peasants and Workers Democratic Party, and 29 experts from Recommendation and Review Expert Committee of Selection Activities, containing 7 academicians of the Chinese Academy of Science and Chinese Academy of Engineering.

Over 700 guests and participants attended the award ceremony, including representatives from hosts - Liu Dianbo, Chairman of PhIRDA, Song Ruilin, Executive President of PhIRDA, Ding Lixin, Deputy Secretary of SIP Party Working Committee, Director of SIP Administrative Committee, Dong Xuesong, Vice General Manager of Health Department of People.cn, representatives from nominated enterprise, prestigious experts, scholars, entrepreneurs and so on.

The final review meeting was held before the award ceremony. 29 experts from Expert Committee voted by secret ballot and sealed the result on the spot. The result of the selection activity was not released to the public until the award ceremony.

Song Ruilin, Executive President of PhIRDA, introduced the background, prize categories, and selection process, and emphasized the major changes of selection rules this year. Taking standard of international rules as reference, 2018 Selection Activities was reformed in the following aspects: changing submission mechanism from self-application to expert-recommendation; free of charge; establishing a recommendation/review committee consisting of authoritative pharmaceutical experts and academicians; carrying out selection by fully adhering to international mechanisms and standards for science prize selection, taking peer review, fair procedure, benefit related persons avoidance, confidential result and so forth; transparent selection procedures from recommendation, preliminary review, second review to final review. In the voting procedure, a vote by open ballot in second review meeting and vote by secret ballot in final review meeting were adopted, which fully respect expert’s opinions, and the authority, justice and fairness of the Selection Activities.

Addressed by Song Ruilin, Executive President of PhIRDA

Ding Lixin, Deputy Secretary of SIP Party Working Committee and Director of SIP Administrative Committee, made opening remarks on behalf of the hosts. He extended a warm welcome for hosting 2018 Selection Activities in Suzhou Industrial Park, and gave high praises for the authority and industrial influence of Selection Activities.

Ding Lixin, Deputy Secretary of SIP Party Working Committee and Director of SIP Administrative Committee, made opening remarks

In the eye-catching releasing, the winners of six awards categories were finally announced.

 “Special Contribution to Pharmaceutical Innovation Award” was awarded to Chen Kaixian, Deputy Chief Engineer of National Science and Technology Major Project for Major New Drug Research and Development, academician of Chinese Academy of Sciences. The award was announced by Jiang Hualiang, academician of Chinese Academy of Sciences, Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and PhIRDA Annual Chairman 2015 - 2016, and Prof. He Wei, Vice Chairperson of CPPCC National Committee, presented 800,000 CNY reward to the winner.

Winner of Special Contribution to Pharmaceutical Innovation: Academician Chen Kaixian (the second from the right), Prof. He Wei (the second from the left), Academician Jiang Hualiang (the first from the left). 

Award for Most Innovative Figure of Drug R&D was awarded to Wu Beili, researcher of Shanghai Institute of Materia Medica of Chinese Academy of Sciences, and Yang Dajun, Chairman of the Board&CEO, Ascentage Pharma Group. Award for Most Innovative Figure of Drug R&D (International Areas) was won by Chen Lieping, professor of Immunobiology, Dermatology and Medical Oncology at the Yale School of Medicine. The awards were announced by Shi Yuankai, Vice President of Cancer Hospital, Chinese Academy of Medical Sciences, and Wang Xiaodong, Member of National Academy of Sciences, USA, Foreign Associate of Chinese Academy of Sciences, Founder of BeiGene, and presented by Zhou Jianmin, Vice Chairperson of Jiangsu Provincial Committee of CPPCC, and Li Yaping, Vice Secretary of Suzhou Municipal Party Committee, Mayor of Suzhou. Prize winners were awarded a bonus of 500,000 CNY.

Winner of Most Innovative Figure of Drug R&D Award (International Areas): Chen Lieping (the middle),

Winners of Most Innovative Figure of Drug R&D Award: Wu Beili (the third from the left), Dr.Yang Dajun (the third from the right);

Award announcers and presenters: Zhou Jianmin (the second from the right), Li Yaping (the second from the left); academician Wang Xiaodong (the first one from the right), Shi Yuankai (the first from the left) 

Award for Most Innovative Figure of Clinical R&D was awarded to Jiang Lixin, Vice President of Fuwai Hospital, Chinese Academy of Medical Sciences and Huo Yong, Director of Department of cardiology and cardiac center of Peking University First Hospital. The awards were announced and presented by Wu Yilong, professor of Guangdong General Hospital, and Ge Junbo, academician of Chinese Academy of Sciences and Director of Cardiology Department, Zhongshan Hospital Fudan University, with reward of 500,000 CNY.

Winners of Most Innovative Figure of Clinical R&D Award: Jiang Lixin (the second from the right), Huo Yong (the second from the left);

Award announcers and presenters: Ge Junbo (the first from the right), Wu Yilong (the first from the left)

Award for Innovative Drug with Most Clinical Value was won by Anlotinib Hydrochloride Capsules from Chia Tai Tianqing Pharma; Award for Innovative Medical Devices was received by Ankon Magnetically Controlled Capsule Endoscopy from Ankon Technologies (Wuhan) Co., Ltd. The awards were announced by Jiang Jiandong, PhIRDA Annual Chairman 2017-2018, Director of Institute of Materia Medica, Chinese Academy of Medical Sciences, and Prof. Wu Xiaoming, former President of China Pharmaceutical University, and presented by Chen Jianfeng, Vice President of Beijing University of Chemical Technology, academician of Chinese Academy of Engineering.

Winner of Innovative Drug with Most Clinical Value Award: Xie Xin from Chiatai Tianqing Pharm (the middle),

Winner of Innovative Medical Device with Most Clinical Value Award:

Ji Pengsong from Ankon Medical Technologies Co., Ltd. (the second from the left)

Award announcers and presenters: Chen Jianfeng (the first from the left), Jiang Jiandong (the second from the right), Wu Xiaoming (the first from the right)

Award for Innovative Pediatric Drug with Most Clinical Value was awarded to Enterovirus Type 71 Inactivated Vaccines developed by Institute of Medical Biology Chinese Academy of Medical Sciences. The award was announced and presented respectively by Prof. Wang Junzhi, chief expert for Biological product testing in National Institutes for Food and Drug Control, and Zhao Kai, academician of the Chinese Academy of Engineering, researcher of National Vaccine & Serum Institute.

 

Winner of Innovative Pediatric Drug with Most Clinical Value Award: You Dan from Institute of Medical Biology Chinese Academy of Medical Sciences (the middle),

Awards announcer and presenter: Wang Junzhi (the left), Zhao Kai (the right)

Award for Most Successful Investment Institutions were awarded by Lilly Asia Ventures, Shenzhen Qianhai YuanMing Asset Management Co., Ltd., Shenzhen GTJA Investment Group Co., Ltd., 6 Dimensions Capital, and Shenzhen Efung Venture Capital Co., Ltd., and announced by Fang Laiying, Vice President of Chinese Hospital Association, and presented by Li Lin, President of Shanghai Institutes for Biological Sciences, academician of the Chinese Academy of Sciences.

Winners of the Most Successful Investment Institutions for Pharmaceutical Innovation Award: Chen Fei from Lilly Asia Ventures (the second from the right), Tian Yuan from Shenzhen Qianhai YuanMing Asset Management Co., Ltd. (the first from the right), Hu Xuefeng from Shenzhen GTJA Investment Group Co., Ltd. (the middle),  Zhu Jinqiao from Shenzhen Efung Venture Capital Co., Ltd. (the second from the left), Zhu Qingsheng from 6 Dimensions Capital (the third from the left);

Awards announcer and presenter: Li Lin (the right), Fang Laiying (the left)

 

Winners, host representatives and VIP Guests: He Wei, Zhou Jianmin, Li Yaping, Wu Qingwen

In the award ceremony, over 700 participants and audiences witnessed the announcement of the final award winners of 2018 “Dushu Lake Prize” Selection Activities of China Pharmaceutical Innovation Brand together, which caught the eyes of the entire pharmaceutical industry, and they were deeply impressed by the authority, fairness, openness and justice of the selection activities, as well as the flourishing growth of the innovative pharmaceutical industry in China. The Selection Activities was held with great success, and all awards were presented to the winners who did make distinctive achievements and contribution, fully reflecting the success of innovative mechanism of 2018 Selection Activities this year.

The development of Selection Activities will further promote the building of innovative pharmaceutical brand in China, publicize new events and Chinese innovative drugs at home and abroad, enhance the innovative ability of pharmaceutical industry in China, making contribution to the increasing competence of innovation internationally. Following the principle of “Justice, Transparency and Fairness”, the Selection Activities will be built as the most authoritative selection for innovative pharmaceutical brand, and keep developing towards the most influential selection in Asia and across the whole world.

Awards Ceremony and VIP Guests